| Autor: |
Koksal UI; Department of Medical Oncology, Faculty of Medicine, Bilim University, Istanbul, Turkey., Pilanci KN, Ordu C, Okutur K, Saglam S, Demir G |
| Jazyk: |
angličtina |
| Zdroj: |
American journal of therapeutics [Am J Ther] 2016 Sep-Oct; Vol. 23 (5), pp. e1226-9. |
| DOI: |
10.1097/MJT.0000000000000189 |
| Abstrakt: |
Trichomegaly is a rare side effect of epidermal growth factor receptor inhibitors. We present here 4 patients who treated with cetuximab (an epidermal growth factor receptor inhibitor) for metastatic colorectal cancer. All of the cases were treated with cetuximab 500 mg/m biweekly in combination protocol. The mean period from the start of the treatment until the development the trichomegaly was 4.75 (3-6) months. In all of the patients after the end of the cetuximab therapy, trichomegaly was regressed. Only 1 case resolved with topical treatment that conjunctivitis with trichomegaly. Trichomegaly is an important ocular toxicity of cetuximab that can cause visual discomfort and corneal damages. However, these side effects usually do not require discontinuation of treatment. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
